IP Library Granted Patent US 7,976,872
Granted Patent B2
US 7,976,872 · App. 11/491,844 · Granted Jul 12, 2011

Method for distributing a pharmaceutically active compound in an excipient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,872
App. No.
11/491,844
Granted
Jul 12, 2011
Kind
B2
Abstract

A process for uniformly distributing a pharmaceutically active particulate material in a pharmaceutically inert particulate material includes steps of providing a first layer of a pharmaceutically inert particulate material, disposing a layer of a pharmaceutically active particulate material on the first layer of pharmaceutically inert particulate material, passing the layers of particulate material through a static mixer, and discharging the blended mixture from the static mixer. The process is particularly useful for blending a low dose, high potency drug having a propensity to stick to process equipment surfaces with pharmaceutically inert particulate materials, such as diluents and/or excipients.

Claims (35)

1. A process for distributing a pharmaceutically active particulate material in a pharmaceutically inert particulate material, comprising:

(a) providing a first layer of a pharmaceutically inert particulate material;

(b) disposing a layer of a pharmaceutically active particulate material on the first layer of pharmaceutically inert particulate material;

(c) passing the layers of particulate material through a static mixer; and

(d) discharging a blended mixture of a pharmaceutically active particulate material and a pharmaceutically inert particulate material.

2. The process of claim 1 , wherein the pharmaceutically active particulate material is loperamide.

3. The process of claim 1 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of 50 milligrams or less.

4. The process of claim 1 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of 20 milligrams or less.

5. The process of claim 1 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of 10 milligrams or less.

6. The process of claim 1 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of 5 milligrams or less.

7. The process of claim 1 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of 2 milligrams or less.

8. The process of claim 1 , wherein the weight ratio of pharmaceutically inert particulate material in one layer to the pharmaceutically active particulate material in an adjacent layer is from about 5:1 to about 50:1.

9. The process of claim 1 , wherein the weight ratio of pharmaceutically inert particulate material in one layer to the pharmaceutically active particulate material in an adjacent layer is from about 5:1 to about 20:1.

10. The process of claim 1 , wherein steps (a) and (b) are repeated a plurality of times to form alternating layers of pharmaceutically active material and pharmaceutically inert material.

11. The process of claim 10 , wherein the plurality of layers are deposited in a dispensing hopper attached to the static mixer.

12. The process of claim 11 , wherein the hopper has a cylindrical upper section with a circular cross section, and wherein a ratio of diameter to height of the cylindrical section of the hopper is from about 1:1.2 to about 1:2.4.

13. The process of claim 1 , wherein the pharmaceutically inert material comprises dextrates.

14. A process for making a pharmaceutical granulation, comprising:

(a) providing a first layer of a pharmaceutically inert particulate material;

(b) disposing a layer of a pharmaceutically active particulate material on the first layer of pharmaceutically inert particulate material;

(c) passing the layers of particulate material through a static mixer;

(d) discharging a blended mixture of a pharmaceutically active particulate material and a pharmaceutically inert particulate material, and

(e) combining and granulating the blended mixture with additional particulate material.

15. The process of claim 14 , wherein the pharmaceutically active particulate material is loperamide.

16. The process of claim 14 , wherein the pharmaceutically active particulate material is a high potency drug administered in a therapeutically effective amount of less than 50 milligrams.

17. A process for making a pharmaceutical tablet, comprising:

(a) providing a first layer of a pharmaceutically inert particulate material;

(b) disposing a layer of a pharmaceutically active particulate material on the first layer of pharmaceutically inert particulate material;

(c) passing the layers of particulate material through a static mixer;

(d) discharging a blended mixture of a pharmaceutically active particulate material and a pharmaceutically inert particulate material;

(e) combining and granulating the blended mixture with additional particulate material to form a granulation, and

(f) compressing the granulation to form a tablet.

18. The process of claim 17 , wherein the pharmaceutically active particulate material is loperamide hydrochloride, the pharmaceutically inert particulate material comprises dextrates, and wherein the dextrates and loperamide hydrochloride are arranged in alternating layers in which the weight ratio of the pharmaceutically inert particulate material in one layer to the pharmaceutically active particulate material in an adjacent layer is from about 5:1 to about 50:1.

19. The process of claim 17 , wherein the pharmaceutically active particulate material is loperamide hydrochloride, the pharmaceutically inert particulate material comprises dextrates, and wherein the dextrates and loperamide hydrochloride are arranged in alternating layers in which the weight ratio of the pharmaceutically inert particulate material in one layer to the pharmaceutically active particulate material in an adjacent layer is from about 5:1 to about 20:1.

20. The process of claim 19 , wherein the additional particulate materials comprise dextrates, a tablet binder, and at least one disintegrant.

Assignments (2)
SECURITY AGREEMENT Recorded Jun 13, 2022
From: L. PERRIGO COMPANY; PBM NUTRITIONALS, LLC; PERRIGO DIABETES CARE, LLC; RANIR, LLC; OMEGA PHARMA INNOVATION & DEVELOPMENT NV; PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY COMPANY
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 060362/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2006
From: ALEXANDER, THOMAS A.
To: L. PERRIGO COMPANY
Reel/Frame 018089/0044 →